Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.

doi:10.1007/s00277-025-06399-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.

Annals of hematology - 1 May 2025

Lin Jinya, Liu Xiupu, Ying Shuangwei, Zhu Yuanyuan, Huang Weijia, Zheng Weiyan, Ye Xiujin, Shi Jimin, Luo Yi, He Jingsong, Cai Zhen, Zhao Yi, Wu Wenjun, He Donghua, Han Xiaoyan, Zheng Gaofeng, Zhao Yanmin, Hu Yongxian, Huang He, Sun Jie

Abstract excerpt

According to the 2022 International Consensus Classification (ICC) guidelines, nine myelodysplasia-related (MDS-related) gene mutations are classified as adverse-risk markers in acute myeloid leukemia (AML) under intensive therapy (INT). Although venetoclax (VEN) has demonstrated clinical benefit in subsets of AML with MDS-related gene mutations (AML-MR), its efficacy across all nine mutations remains unclear. In...

Read the complete abstract on PubMed

Topics

Humans
Leukemia, Myeloid, Acute
Sulfonamides
Female
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Bridged Bicyclo Compounds, Heterocyclic

Aged

Middle Aged

Retrospective Studies

Mutation

Adult

Aged, 80 and over

Myelodysplastic Syndromes

Antineoplastic Agents

Remission Induction

Treatment Outcome

Hematopoietic Stem Cell Transplantation

Source

Open in PubMed Open full text

Identifiers

PMID: 40399531
DOI: 10.1007/s00277-025-06399-7
PMCID: PMC12141368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.PMID 40399531Read ↗

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AMLSemantic proximity Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.Semantic proximity Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.Semantic proximity Read ↗

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.Semantic proximity Read ↗

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.